Tomotherapy radiation treatment planning software gains FDA clearance

9 February 2009

Swedish company RaySearch Laboratories AB (STO:RAYB) and TomoTherapy Inc have announced that their jointly produced new software solution, SharePlan, has received clearance by the FDA for market launch in the US.

SharePlan is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy Hi-Art systems and conventional linear accelerators. The product uses sophisticated algorithms to automatically generate a selection of deliverable high-quality IMRT plans based on an existing Hi-Art plan.

This time-saving concept is an important tool for optimizing patient benefit and throughput at clinics that are introducing a Hi-Art system into an environment with existing conventional linear accelerators.

“We put great pride in our collaboration with TomoTherapy and have been working intensely on this product for little over a year, so of course it feels very rewarding that we now reach the market. Automatic plan generation is a revolutionary treatment planning concept that offers unparalleled user-friendliness and has the potential to dramatically reduce the everyday workload spent on routine tasks,” says Johan Löf, President of RaySearch.

“Our success is not just based upon delivering the highest quality radiation therapy,” according to Del Coufal, Vice President of Marketing for TomoTherapy. “We understand how important it is for TomoTherapy technology to seamlessly integrate into a cancer centre, regardless of the type of surrounding equipment the centre also uses. By aligning with industry-leading strategic partners like RaySearch, we are able to make it easy for any centre to easily adopt our revolutionary radiotherapy system.”

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. Tomotherapy radiation treatment planning software gains FDA clearance 9 February 2009 Swedish company RaySearch Laboratories AB (STO:RAYB) and TomoTherapy Inc have announced that their jointly produced new software solution, SharePlan, has received clearance by the FDA for market launch in the US. SharePlan is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy Hi-Art systems and conventional linear accelerators. The product uses sophisticated algorithms to automatically generate a selection of deliverable high-quality IMRT plans based on an existing Hi-Art plan. This time-saving concept is an important tool for optimizing patient benefit and throughput at clinics that are introducing a Hi-Art system into an environment with existing conventional linear accelerators. “We put great pride in our collaboration with TomoTherapy and have been working intensely on this product for little over a year, so of course it feels very rewarding that we now reach the market. Automatic plan generation is a revolutionary treatment planning concept that offers unparalleled user-friendliness and has the potential to dramatically reduce the everyday workload spent on routine tasks,” says Johan Löf, President of RaySearch. “Our success is not just based upon delivering the highest quality radiation therapy,” according to Del Coufal, Vice President of Marketing for TomoTherapy. “We understand how important it is for TomoTherapy technology to seamlessly integrate into a cancer centre, regardless of the type of surrounding equipment the centre also uses. By aligning with industry-leading strategic partners like RaySearch, we are able to make it easy for any centre to easily adopt our revolutionary radiotherapy system.” Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.